Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

A qualitative review of the neurophysiological underpinnings of fatigue in multiple sclerosis.
NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis.
Selective Blockade of CD28-Mediated T Cell Costimulation Protects Rhesus Monkeys against Acute Fatal Experimental Autoimmune Encephalomyelitis.
In vivo Positron Emission Tomography Imaging Demonstrates Diminished Microglial Activation after Fingolimod Treatment in an Animal Model of Multiple Sclerosis.
You're the Flight Surgeon.
Progression and CSF Inflammation after Eradication of Oligoclonal Bands in an MS Patient Treated with Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma.
Neuroprotection and repair in multiple sclerosis.
Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry.
Future directions of multiple sclerosis rehabilitation research.
A changing treatment landscape for multiple sclerosis: challenges and opportunities.
Learning to fly with broken wings - forcing a reappraisal of time and space.
Human pluripotent stem cell-derived neural constructs for predicting neural toxicity.
Neuromyelitis optica spectrum disorder and varicella-zoster infection.
Long live the axon. Parallels between ageing and pathology from a presynaptic point of view.
Simultaneous Pml-Iris After Discontinuation of Natalizumab in A Patient With MS.
Treatment of cognitive impairment in multiple sclerosis: position paper.
Sunshine and multiple sclerosis.
Current understanding on the role of standard and immunoproteasomes in inflammatory/immunological pathways of multiple sclerosis.
Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg.
Changes in B and T-cell subsets and NMO-IgG levels after immunoglobulins and rituximab treatment for an acute attack of neuromyelitis optica.
Clinical baseline factors predict response to natalizumab: their usefulness in patient selection.
Disruption of structural and functional networks in long-standing multiple sclerosis.
Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings.
Secondary progression and innate immunity in NMO: A possible link to alemtuzumab therapy?
Intravenous immunoglobulin in neurology-mode of action and clinical efficacy.

Pages